Banking politics are stifling Jamaica’s unique opportunity to foster a medicinal cannabis industry. It’s reassuring to see senior members of the Jamaican government engaging with the industry to actively find solutions to these significant problems. Full article link here
With the demand for CBD so high, sub-par products have been flooding the market. It is incredibly important to source from businesses with stringent testing around growing and manufacturing. Full article hereÂ
Given the popularity of CBD, biotech firms are attempting to synthesis CBD to meet expanding demand. Synthesised CBD would lack the entourage effect of natural CBD, so it will be interesting to see how the efficacy of these alternatives stacks up. Full article link here
With 25% of 192 million people polled across three countries stating that their use is partly medicinal. The market segment of medical cannabis is in for a surge of demand and we are prepared to meet that opportunity. See full article here
The potential for over-the-counter CBD access in Australia has led to questions surrounding the maximum doses permitted. The Lamber Initiative shows that 60 milligrams a day may not be high enough to benefit patients. However, this still creates an opportunity for Cannim to offer Australians the relief they need and remains a space to watch...
The potential for over-the-counter CBD access in Australia has led to questions surrounding the maximum doses permitted. The Lamber Initiative shows that 60 milligrams a day may not be high enough to benefit patients. However, this still creates an opportunity for Cannim to offer Australians the relief they need and remains a space to watch....
2017 marked the 25th anniversary of one of the most important discoveries in cannabinoid science. On March 24, 1992, LumÃr HanuÅ¡, a Czech analytical chemist working in Israel with American pharmacologist William Devane, isolated the first known endocannabinoid in the human brain. They named it anandamide, after the Sanskrit word for joy or bliss. Link...
